Alfresa Holdings Corp
TSE:2784
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.1), the stock would be worth ¥2 522.42 (5% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | ¥2 391 |
0%
|
| 3-Year Average | 0.1 | ¥2 522.42 |
+5%
|
| 5-Year Average | 0.1 | ¥2 335.87 |
-2%
|
| Industry Average | 1.7 | ¥51 307.55 |
+2 046%
|
| Country Average | 1.1 | ¥33 501.9 |
+1 301%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥278.1B
|
/ |
Jan 2026
¥3.1T
|
= |
|
|
¥278.1B
|
/ |
Mar 2026
¥3.1T
|
= |
|
|
¥278.1B
|
/ |
Mar 2027
¥3.2T
|
= |
|
|
¥278.1B
|
/ |
Mar 2028
¥3.3T
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
A
|
Alfresa Holdings Corp
TSE:2784
|
434.5B JPY | 0.1 | 12.9 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
102.7B USD | 0.3 | 23.7 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.4B USD | 0.2 | 37.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
60.7B USD | 0.2 | 37.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
48.5B USD | 0.2 | 29.2 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
31.6B AUD | 2.9 | 35.1 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.8B CNY | 0.3 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.8B USD | 0.9 | 22.1 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.2B CNY | 1.7 | 20.9 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.5B HKD | 0 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.7 |
| Median | 1.1 |
| 70th Percentile | 2 |
| Max | 12 107 466 |
Other Multiples
Alfresa Holdings Corp
Glance View
In the bustling world of pharmaceuticals and healthcare, Alfresa Holdings Corp. stands as a notable player, weaving a complex web that connects various facets of the medical industry in Japan and beyond. Founded in 2003 as a result of a merger, Alfresa has carved a niche for itself in the logistics and distribution sector of pharmaceuticals. The company's core strength lies in its ability to streamline the journey of medicinal products from manufacturers to healthcare providers. This massive undertaking is facilitated by an intricate network of strategic partnerships and a robust supply chain, ensuring that pharmacies, hospitals, and clinics receive the necessary products promptly and efficiently. Alfresa’s revenue streams are as diversified as the products it handles. Beyond its role as a distributor, the company has expanded into the manufacturing of its own pharmaceuticals, further solidifying its position in the market. This vertical integration allows it not only to distribute third-party products but to add value by developing and marketing its proprietary offerings. In an industry rife with competition and regulatory challenges, such a strategy provides a dual advantage: a stable supply for its distribution networks and an additional revenue channel. Alfresa's commitment to innovation and efficiency has enabled it to maintain steady growth, balancing between its traditional distribution roots and its forays into pharmaceutical production, thus affirming its status as a key cog in the healthcare industry’s machine.